A detailed history of Crewe Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Crewe Advisors LLC holds 563 shares of VRTX stock, worth $253,558. This represents 0.03% of its overall portfolio holdings.

Number of Shares
563
Previous 520 8.27%
Holding current value
$253,558
Previous $243,000 7.41%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $19,780 - $21,748
43 Added 8.27%
563 $261,000
Q2 2024

Jul 29, 2024

BUY
$392.81 - $485.53 $1,178 - $1,456
3 Added 0.58%
520 $243,000
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $210,775 - $230,623
517 New
517 $216,000
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $8,174 - $9,149
26 Added 4.94%
552 $194,000
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $22,658 - $25,848
-80 Reduced 13.2%
526 $165,000
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $30,004 - $33,755
-105 Reduced 14.77%
606 $175,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $10,131 - $11,304
37 Added 5.49%
711 $206,000
Q2 2022

Aug 02, 2022

BUY
$234.96 - $292.55 $49,106 - $61,142
209 Added 44.95%
674 $190,000
Q1 2022

Apr 27, 2022

BUY
$221.42 - $260.97 $70,854 - $83,510
320 Added 220.69%
465 $121,000
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $25,666 - $32,400
145 New
145 $32,000
Q4 2020

Jan 27, 2021

SELL
$207.01 - $276.09 $6,210 - $8,282
-30 Closed
0 $0
Q3 2020

Oct 13, 2020

BUY
$255.65 - $303.1 $7,669 - $9,093
30 New
30 $8,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.